Accéder au contenu
Merck

Distinct amyloid-β and tau-associated microglia profiles in Alzheimer's disease.

Acta neuropathologica (2021-02-21)
Emma Gerrits, Nieske Brouwer, Susanne M Kooistra, Maya E Woodbury, Yannick Vermeiren, Mirjam Lambourne, Jan Mulder, Markus Kummer, Thomas Möller, Knut Biber, Wilfred F A den Dunnen, Peter P De Deyn, Bart J L Eggen, Erik W G M Boddeke
RÉSUMÉ

Alzheimer's disease (AD) is the most prevalent form of dementia and is characterized by abnormal extracellular aggregates of amyloid-β and intraneuronal hyperphosphorylated tau tangles and neuropil threads. Microglia, the tissue-resident macrophages of the central nervous system (CNS), are important for CNS homeostasis and implicated in AD pathology. In amyloid mouse models, a phagocytic/activated microglia phenotype has been identified. How increasing levels of amyloid-β and tau pathology affect human microglia transcriptional profiles is unknown. Here, we performed snRNAseq on 482,472 nuclei from non-demented control brains and AD brains containing only amyloid-β plaques or both amyloid-β plaques and tau pathology. Within the microglia population, distinct expression profiles were identified of which two were AD pathology-associated. The phagocytic/activated AD1-microglia population abundance strongly correlated with tissue amyloid-β load and localized to amyloid-β plaques. The AD2-microglia abundance strongly correlated with tissue phospho-tau load and these microglia were more abundant in samples with overt tau pathology. This full characterization of human disease-associated microglia phenotypes provides new insights in the pathophysiological role of microglia in AD and offers new targets for microglia-state-specific therapeutic strategies.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-Olig2, clone 211F1.1, conjugué à l'Alexa Fluor 488 | MABN50A4, clone 211F1.1, from mouse, ALEXA FLUOR 488